body > *:not(noscript) { display: none !important; } noscript { display: block !important; } .no-js-warning { display: flex !important; min-height: 100vh; align-items: center; justify-content: center; padding: 20px; background: #f8f9fa; text-align: center; } .no-js-card { max-width: 500px; padding: 30px; border-radius: 12px; background: white; box-shadow: 0 10px 30px rgba(0,0,0,0.08); font-family: Arial, sans-serif; } .no-js-card h1 { margin-bottom: 10px; }

JavaScript Required

JavaScript is required for this website to work correctly and provide a smooth user experience. Please enable JavaScript in your browser, then refresh the page.

Back to PharmaIndex

Eurepa-V 0.5/0.3 Tablet

Repaglinide (0.5mg) + Voglibose (0.3mg)

Train on this drug

Drug details

API

Repaglinide (0.5mg) + Voglibose (0.3mg)

Drug classification

Dosage form

API strength per dosage

Dose

Mechanism of action

Indications

Treatment of Type 2 diabetes mellitus

Side effects

Hypoglycemia low blood glucose level Abdominal pain Diarrhea Flatulence Upper respiratory tract infection Headache

Pregnancy category

Precautions

Contraindications

Interaction checker

Check interactions

Ask about possible interactions, counseling points, and safety considerations for this medicine.

Drug interaction assistant

Ask about Eurepa-V 0.5/0.3 Tablet with another medicine, food, condition, or counseling concern.

PharmaProLearn

Excel Beyond Limits